Genmab A/S (GMAB) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
United Therapeutics (UTHR) has outperformed Genmab A/S (GMAB) over the past year, gaining 18.7% versus a gain of 10.1%. Over five years, UTHR leads with a +184.8% price change compared with -18.9% for GMAB. United Therapeutics is the larger company by market cap ($23.42 billion vs $22.78 billion), about 1.0 times the size, while Genmab A/S is growing revenue faster (+19.2% vs +10.6%).
On valuation, United Therapeutics trades at a lower forward P/E (16.2x vs 24.3x for Genmab A/S). United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus 25.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | UTHR |
|---|---|---|
| Share price | $37.04 | $545.93 |
| Market cap | $22.78B | $23.42B |
| 1-day change | +2.75% | +2.47% |
| YTD return | +17.05% | +9.34% |
| 1-year return | +10.11% | +18.68% |
| 5-year return | -18.86% | +184.80% |
| P/E ratio (TTM) | 29.17 | 19.55 |
| Forward P/E | 24.29 | 16.16 |
| EPS (TTM) | $1.27 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $3.18B |
| Revenue growth (YoY) | +19.19% | +10.61% |
| Net income (latest FY) | $963.00M | $1.33B |
| Gross margin | 93.60% | 87.92% |
| Operating margin | 28.63% | 46.89% |
| Net margin | 25.89% | 41.94% |
| 52-week high | $40.17 | $609.35 |
| 52-week low | $23.62 | $409.07 |
| Distance from 52-week high | -7.79% | -10.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +16.68% | +19.00% |
| Average volume | 2.83M | 672.80K |
| Shares outstanding | 614.90M | 42.89M |
| Employees | 3,119 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Genmab A/S trades at a higher earnings multiple (29.2x vs 19.6x trailing P/E).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus 25.9 cents for Genmab A/S.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs +10.61%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
GMAB vs UTHR FAQ
Which is bigger, Genmab A/S or United Therapeutics?
United Therapeutics (UTHR) is larger, with a market capitalization of $23.42B compared with $22.78B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or UTHR?
UTHR returned +18.68% over the past 12 months, compared with +10.11% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or UTHR?
UTHR has the lower trailing P/E at 19.6, versus 29.2 for GMAB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Genmab A/S and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.